Abstract
A retrospective analysis of monitoring of patients with primary or recurrent non-muscle invasive bladder cancer (NMIBC) treated with transurethral resection (TUR) with or without restaging TUR or intravesical therapy in State Institution N.N. Alexandrov National Cancer Centre of Belarus in 2004–2012 was performed with an objective to develop a prognostic classification for NMIBC. The analysis included 921 patients. In the multivatiate analysis independent predictors of recurrence were recurrence rate, number of tumors, tumor size, grade, and tumor location in the trigone, anterior wall, dome, and prostatic urethra; predictors of progression were age, recurrence rate, tumor size, grade, and tumor location in the trigone and prostatic urethra. The patients were divided into 4 groups with low, intermediate, high and very high risk. Corrected C-index values for the developed classifications of recurrence and progression risks were 0.635 and 0.740 respectively, which were significantly higher than C-indices for the European Organization for Research and Treatment of Cancer tables.
Highlights
Alexandrov National Cancer Centre of Belarus in 2004–2012 was performed with an objective to develop a prognostic classification for non-muscle invasive bladder cancer (NMIBC)
The patients were divided into 4 groups with low, intermediate, high and very high risk
Corrected C-index values for the developed classifications of recurrence and progression risks were 0.635 and 0.740 respectively, which were significantly higher than C-indices for the European Organization for Research and Treatment of Cancer tables
Summary
Для разработки классификации использовали ретроспективную базу данных, содержащую все случаи лечения пациентов с первичным или рецидивным РМПБМИ с использованием ТУР в РНПЦ ОМР им. Из анализа были исключены все случаи нерадикального лечения, выполнения цистэктомии или нестандартного лечения (фотодинамическая терапия). Также исключались пациенты с наличием подтвержденной мышечной инвазии, в том числе в анамнезе, отсутствием гистологической верификации или непереходно-клеточным морфологическим типом опухоли, а также с синхронными или предшествующими лечению опухолями верхних мочевых путей. Были исключены все случаи карциномы in situ (carcinoma in situ, CIS) без сопутствующих папиллярных опухолей, случаи без доступных данных о наблюдении или с длительностью наблюдения < 12 мес после ТУР. Для окончательного анализа из 372 случаев неоднократного лечения у 153 пациентов случайным образом отобрано по 1 случаю на каждого пациента, в результате чего в базе данных остался 921 случай. Дополнительные воздействия: Additional interventions: ФДД PDD ранняя однократная инстилляция single early instillation внутрипузырная терапия intravesical therapy
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
